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Glucocorticoids (GCs) represent a mainstay of treatment
in most chronic inflammatory diseases. However, many
forms of vasculitis relapse after cessation of GC medica-
tion or remain primarily unresponsive. Assuming the vas-
culature and especially endothelial cells (ECs) as origin of
the inflammatory process we investigated the effects of
GCs on ECs in comparison to monocytes. We treated
human micro- and macrovascular ECs as well as human
monocytes for 4 h and 16 h with GC or GC + TNF or pre-
treated ECs with GC followed by TNF stimulation. Testing
several genes by quantitative RT-PCR as well as by micro-
array analysis considering more than 17,000 genes we
found no significant gene expression changes in ECs nei-
ther with GC alone nor for GC on TNF-induced genes
which was in strict contrast to the impressive GC-response
of monocytes. We checked that all known GC receptor
(GR) subtypes as well as potential cofactors of GC were
readily expressed in untreated and inflammatory stimu-
lated ECs. However, in immunofluorescence stainings we
surprisingly found that GC treatment failed to induce a
nuclear shift of the GR in ECs in contrast to a substantial
shift in steroid-sensitive monocytes.
Summarizing our results indicate that the molecular pre-
requisites for the implementation of GC effects on gene
regulation are not given in ECs in contrast to myeloid
cells. The anti-inflammatory effects of GCs in vasculitis
might primarily act on infiltrating leucocytes without tar-
geting ECs which may be the molecular basis for sympto-
matic effects but lack of long-lasting success of GC-
treatment in many forms of vasculitis.
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